Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Invivyd reported Q1 2026 net product revenue of $13.7 million for PEMGARDA, a 22% increase from $11.3 million in Q1 2025. The company's cash and cash equivalents stood at $184.2 million as of March 31, 2026, with an additional $20 million raised in April 2026 through an ATM offering facility. R&D expenses increased to $30.7 million in Q1 2026 from $10.6 million in Q1 2025, primarily due to the DECLARATION clinical trial for VYD2311.
Key figures
- Revenue
- 13744000
- Revenue Yoy
- 22%
- Net loss
- 41400000
- Sga expenses
- 25117000
- R and d expenses
- 30731000
- Total shares outstanding
- 282803863
- Cash and cash equivalents
- 184153000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.